Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 152-159

  Thomas, Howard C ^a   Torok M E ^a   Forton, D M ^a   Taylor Robinson, S D ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Extrahepatic site; Hepatitis C; Interferon ; Mathematical modelling; Mechanisms of action; Ribavirin

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

CONFERENCE PAPER; DISEASE ACTIVITY; DRUG MECHANISM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MATHEMATICAL MODEL; PRIORITY JOURNAL; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 0033429408     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80393-6     Document Type: Conference Paper

References (57)

1. Seeff LB. Natural history of hepatitis C. Hepatology 1997: 26 (Suppl 1); 21S-28S.
2. Lau JYN. Mechanisms of hepatic toxity. IV. Pathogenetic mechanisms involved in hepatitis C virus-induced liver diseases. Am J Physiol 1998: 275 (6 Pt 1): G1217-20.
3. Tibbs C, Donaldson P, Underbill J, Thomson L, Manabe K, Williams R. Evidence that the HLA DQA1 03 allele confers protection from the chronic HCV-infection in Northern European Caucasoids. Hepatology 1996: 24: 1342-1345.
4. Cramp ME, Carucci P, Underbill J, Naoumov NV, Williams R, Donaldson PT. Association between HLA class II genotype and spontaneous clearance of hepatitis C viraemia. J Hepatol 1998: 29 (2): 207-213.
5. Lechmann M, Ihlenfeldt HG, Braunschweiger I, Giers G, Jung G, Matz B et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996: 24: 790-795.
6. Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner AJ et al. T-Iymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993: 104: 580-587.
7. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996: 98: 706-714.
8. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992: 149: 3339-3344.
9. Cerny A, McHutchison JG, Pasquinelli C, Brown ME, Brothers MA, Grabscheid B et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995: 95: 521-530.
10. Rehermann B, Chang KM, McHutchison JG, Kokka R, Houghton M, Chisari FV et al. Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest 1996: 98: 1431-1440.
11. Kumar U, Monjardino J, Thomas HC. Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 1994: 106: 1072-1075.
12. Booth JL, Waters J, Brown JL, Thomas HC. The cellular tropism of HCV. J Hepatol 1995: SuppI 1 23: 104.
13. Lerat H, Berby F, Trabaud MA Vidalin O, Major M, Trepo C et al. Specific detection of hepatitis C minus strand RNA in haematopoietic cells. J Clin Invest 1996: 97 (3): 845-851.
14. Lerat H, Rumin S, Habersetzer F, Berby F, Trabaud MA, Trepo C et al. In v/vo tropism of hepatitis C virus genomic sequences in haematopoietic cells: influence of viral load, viral genotype and cell phenotype. Blood 1998: 91 (10): 3841-3849.
15. Foster GR, Goldin RD, Main J, Murray-Lyon I, Hargreaves S, Thomas HC. Management of chronic hepatitis C: clinical audit of biopsy based management algorithm. Br Med J 1997: 315 (7106): 453158.
16. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996: 25 (5): 591598.
17. Poynard T, Marcellin P, Lee SL, Niederau C, Minuk GS, Ideo G et al. Randomised trial of intereferon 2b plus ribavirin for 48 weeks or 24 weeks versus interferon a2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus. Lancet 1998: 352: 1426-1432.
18. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339: 1485-1492.
19. Foster GR, Finter NB. Are all subtypes of interferons equivalent? J Viral Hepat 1998: 5 (3):143-152.
20. Foster GR, Rodrigues O, Ghouze F, Schulte-Frohlinde E, Testa D, Liao MJ et al. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. J Interferon Cytokine Res 1996: 16 (12): 10271033.
21. Enomoto N, Sakuma I, Asahina Y Kurosaki M, Murakami, Yamamoto C et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus Ib. J Clin Invest 1995: 96: 224-230.
22. Pignatelli M, Waters J, Brown D et al. HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology 1986: 6 (3): 349-353.
23. Rogge L, Barberis-Maino L, Biffi M, Passini N, Presky DH, Gubler U et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 1997: 185 (5): 825-831.
24. Gately MK. Interleukin-12: potential clinical applications in the treatment of chronic viral hepatitis. J Viral Hepat 1997: 4 Suppl 1: 33-39.
25. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ et al. Hepatitis C Viral dynamics in viro and the antiviral efficacy of interferon-cr therapy. Science 1998: 282: 103-107.
26. Nelson DR, Marousis CG, Ohno T, Davis GL, Lau JY. Intrahepatic hepatitis C virus specific cytotoxic T lymphocyte activity and response to interferon alpha therapy in chronic hepatitis C. Hepatology 1998: 28 (1): 225-230.
27. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M et al. Modeling the impact of interferon alpha treatment on liver fibrosis progression in chronic hepatitis C. Gastroenterology 1999: 116:378-386.
28. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S et al. Randomised trial of effect of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995: 346: 1051-1055.
29. Schalm SW, Fattovich G, Brouwer JT. Therapy of hepatitis C: patients with cirrhosis. Hepatology 1997: 26 (3 Suppl 1): 128S132S.
30. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F et al. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997: 27 (1): 201-205.
31. Tsutsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S et al. Reduced plasma transforming growth factor-beta 1 levels in patients with chronic hepatitis C after interferon-alpha therapy: association with regression of hepatic fibrosis. J Hepatol 1999: 30 (1): 1-7.
32. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the JAKSTAT pathway. Hepatology 1998: 28 (4): 312A.
33. Gale M Jr, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997: 230 (2): 217-227.
34. Gale M Jr, Blakely CM, Kwieciszewski B, Tan SL, Dossett M, Tang NM et al. Control of PKR protein kinase by hepatitis C virus nonstructural protein 5A: molecular mechanisms of kinase regulation. Mol Cell Biol 1998: 19 (9): 5208-5218.
35. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus Ib. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995: 96 (1): 224-230.
36. Paterson M, Laxton CD, Sully R et al. The non-structural 5a protein of the hepatitis C virus blocks the antiviral effects triggered by IFN-a. Hepatology 1998: 28 (4) 2: 370A.
37. Ray RB, Meyer K, Steele R, Shrivastava A, Aggarwal BB, Ray R. Inhibition of tumor necrosis factor (TNF alpha) mediated apoptosis by hepatitis C virus core protein. J Biol Chem 1998: 273(4): 2256-2259.
38. Matsumoto M, Hsieh TY, Zhu N, Van Arsdale T, Hwang SB, Jeng KS et al. Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol 1997: 71(2): 1301-1309.
39. Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996: 226(2): 176-182.
40. Bekkering FC, Brouwer JT, Leroux-Roels G, Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high dose interferon therapy in non-responders to standard therapy. J Hepatol 1998: 28(6): 960-964.
41. Jacyna MR, Brooks MG, Loke RH, Main J, Murray-Lyon IM, Thomas HC. Randomised controlled trial of Interferon alpha (lymphoblastoid interferon) in chronic non-A, non-B hepatitis. Br Med J 1989: 298: 80-82.
42. Nowak MA, Bonhoeffer S, Hill M, Boehma R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sei USA 1996: 93: 43984402.
43. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998: 27: 209-212.
44. Forton D, Fletcher A, Talwar N et al. Does hepatitis C virus infect the brain? A proton magnetic resonance study. Proc 7th Ann Meet Int Soc Magn Reson Med (Philadelphia) 1999.
45. Marcus CD, Taylor-Robinson SD, Sargentoni J, Ainsworth JG, Prize G, Easterbrook PJ et al. 'H MR spectroscopy of the brain in HIV-1-seropositive subjects: evidence for diffuse metabolic abnormalities. Metab Brain Dis 1998: 13: 123-136.
46. Bell JE. The neuropathology of adult HIV infection. Rev Neurol (Paris) 1998: 154 (12): 816-829.
47. Barron KD. The microglial cell. A historical review. J Neurol Sei 1995: 134 Suppl: 57-68.
48. Lawson LJ, Perry VH, Gordon S. Turnover of resident microglia in the normal adult mouse brain. Neuroscience 1992:48 (2): 405415.
49. Okuda M, Hino K, Korenaga M, Yamaguchi Y, Katoh Y, Okita K. Differences in hypervariable region 1 quasipecies of hepatitis C virus in human serum, peripheral blood mononuclear cells and liver. Hepatology 1999: 29: 217-222.
50. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Enel J Med 1998: 339: 1493-1499.
51. Robins RK, Revankar GR, McKernan PA, Murray BK, Kirsi JJ, North JA. The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity of ribavirin and selenazofurin. Adv Enzyme Regul 1985: 24: 29-43.
52. Jarvis SM, Thorn JA, Glue P. Ribavirin uptake in human erythrocytes and the involvement of nitrobenzylthionisine-sensitive (es)-nucleotide transporters. Br J Pharmacol 1998: 123 (8): 1587-1592.
53. Fridland A, Connelly MC, Robbins TJ. Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5'-nucIeotidase. Cancer Res 1986: 46 (2): 532-537.
54. Pravdina NF, Kraevskii AA, Skaptsova NV, Florent'ev VL, Galegov GA. Inhibition of influenza virus A RNA-polymerase activity by various 3'-amino-3'-deoxy-and 3'-azido-3'-deoxyribonucleoside-5'-triphosphates. Mol Gen Mikrobiol Virusol 1987: (2): 3942.
55. Lohmann V, Korner F, Herian U, Bartenschlager R. Biochemical properties of hepatitis B NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. J Virol 1997: 71 (11): 8416-8428.
56. Sizova DV, Kolupaeva VG, Pestova TV, Shatsky IN, Hellen CU. Specific interaction of eukaryotic traslation initiation factor 3 with the 5' nontranslated regions of hepatitis C virus and classical swine fever virus RNAs. J Virol 1998: 72 (6): 4775-4782.
57. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper Thl/Th2 subset balance in hepatitis B and C virus-specific Immune responses. J Gen Virol 1998: 79 (Ft 10): 2381-2391.